Recce shares are flying high in Tuesday trade.
The post ‘The largest unmet medical need in human health’: Why this ASX biotech share is surging 28% today appeared first on The Motley Fool Australia. –
TheÂ Recce Pharmaceuticals LtdÂ (ASX: RCE) share price is rebounding after hitting a near multi-year low of 56 cents yesterday.
This comes after the pharmaceutical company provided an update on its development of a new class of synthetic anti-infectives.
At the time of writing, the ASX biotech share is soaring 28.32% to 73 cents.
Whatâs pushing the Recce share price higher?
The company has reportedÂ positive resultsÂ for its broad-spectrum antibiotic Recce 327 drug today.
The phase I study assessed the safety and tolerability of Recce 327 in patients with sepsis.
As such, investigators reviewed the data and found that all 10 male subjects indicated a good safety and tolerability record.
The healthy patients received the cohort six dosing at 4,000mg â an 80-fold increase from cohort one at 50mg.
Following the successful results, the Independent Safety Committee will carefully review the cohort six data. Once completed, the Committee will make a recommendation for the dosage limit and the commencement of testing with the next group of patients.
What did Recce management say?
Recce CEO James Graham commented:
We are pleased with these data which builds on previous results and strongly supports the potential of RECCE 327 as a new treatment option for patients with sepsis.
We look forward to continuing to work with the Independent Safety Committee and further evaluating RECCE 327âs safety and tolerability profile in additional cohorts.
Recce is conducting the study at Adelaide’s CMAX clinical trial facility. It is seeking to evaluate seven to 10 healthy subjects per dose across eight cohorts.
Recce is aiming to wrap up the phase I trial by the second quarter of 2022.
In addition, the PEW Charitable Trusts global antibiotic pipeline review noted that âR327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human healthâ.
Recce share price snapshot
The ASX biotech share has tumbled 33% in 2022 despite todayâs outstanding gains.
For context, the S&P/ASX 200 Healthcare (ASX: XHJ) sector is down 15% over the same time frame.
Based on todayâs price, Recce presides a market capitalisation of roughly $113.71 million.
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of January 12th 2022
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
2 good reasons to become an ESG investor — and 1 reason you shouldn’t
Fortescue share price rebounds 3% today
What’s boosting the Qantas share price on Tuesday?
How to start investing in stocks: This ASX 200 share is where Iâd begin
Hereâs why the Beach Energy share price is leaping 4% today
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.